Sera Prognostics insiders sold shares as the company reported lower-than-expected Q4 earnings.

Sera Prognostics Inc., a women's health company, saw several insiders sell shares recently. CFO Austin Aerts and Director Joshua Phillips made significant sales, reducing their ownership. The company's Q4 earnings missed expectations, with a loss of $0.24 per share versus estimates of $0.22. Institutional investors hold 54.64% of the stock. Sera Prognostics develops the PreTRM test, a biomarker test to predict spontaneous preterm birth.

January 15, 2025
6 Articles